Table 1.
Top 25 gene expression pathways increased in common on day 22 (n = 3) and on day 43 (n = 2), vs day 1
| Pathway | Day 22 VS D1 | Day 43 VS D1 | ||
|---|---|---|---|---|
| # | Genes with increased expression d22 vs dl | # | Genes with increased expression d43 vs d1 | |
| Allograft rejection | 17 | CXCL9,CXCL11,C3,CXCL12,STAT1,CXCL13,C2,HLA-DRB3,HLA-DRA,HLA-DMB,HLA-DRB1,HLA-DPA1,HLA-DRB4,CD80,HLA-DMA,HLA-DPB1,CD86 | 1 | STAT1 |
| Regulation of toll-like receptor signaling pathway | 12 | CXCL11,CXCL9,CXCL10,CD86,TLR7,PIK3CG,CCL5,STAT1,CD80,TLR4,CD14,CD180 | 3 | CCL4,CCL5,STAT1 |
| Toll-like receptor signaling pathway | 11 | CXCL11,CXCL9,CXCL10,CD86,TLR7,PIK3CG,CCL5,STAT1,CD80,TLR4,CD14 | 3 | CCL4,CCL5,STAT1 |
| Complement and coagulation cascades | 9 | C1QB,C1QA,C1S,C2,C3,SERPING1,C3AR1,CFH,SERPINA1 | 1 | C1QA |
| Type II interferon signaling (IFNG) | 9 | STAT1,GBP1,PSMB9,OAS1,CXCL10,CYBB,IFIT2,EIF2AK2,CXCL9 | 2 | STAT1,GBP1 |
| Interferon alpha/beta signaling | 7 | STAT1,IFITM1,IFIT2,IFIT3,IFIT1,XAF1,IFI6 | 2 | STAT1,IFIT3 |
| TCR signaling pathway | 7 | FYB,ITK,CD3E,CD3D,CD3G,CD4,TNFRSF9 | 4 | CBLB,FYB,CD3G,ICOS |
| GPCRs, class A rhodopsin-like | 6 | C3AR1,CMKLR1,PTGER4,P2RY14,GPR174,GPR65 | 2 | GPR174,GPR171 |
| Human complement system | 6 | CFH,C2,C3,SELL,SELPLG,CFB | 1 | LRP2 |
| Complement activation, classical pathway | 5 | C1QA,C1QB,C1S,C2,C3 | 1 | C1QA |
| TSLP signaling pathway | 5 | STAT1,STAT4,IL7R,HCK,LYN | 1 | STAT1 |
| Cell surface interactions at the vascular wall | 4 | SELPLG,CD48,CD2,INPP5D | 1 | CD2 |
| IL-2 signaling pathway | 4 | STAT1,IL2RG,IL2RB,NMI | 3 | STAT1,IL2RG,IL2RB |
| Inflammatory response pathway | 4 | IL2RG,IL2RB,CD86,CD80 | 2 | IL2RG,IL2RB |
| Nuclear receptors meta-pathway | 4 | ALOX5AP,BIRC3,SRGN,SERPINA1 | 1 | SRGN |
| EGF/EGFR signaling pathway | 3 | STAT1,PLSCR1,INPP5D | 2 | STAT1,CBLB |
| Glucocorticoid receptor pathway | 3 | ALOX5AP,BIRC3,SRGN | 1 | SRGN |